Evoq Remedies Ltd

Evoq Remedies Limited has received an extension for its 16th Annual General Meeting (AGM) for the financial year ended March 31, 2026. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP). The Registrar of Companies (ROC), Ahmedabad, has granted a one-month extension, moving the due date for the AGM from September 30, 2026, to October 30, 2026. The company is advised to ensure future compliance with the Companies Act, 2013.

Evoq Remedies Ltd has announced the closure of its trading window for directors, promoters, designated persons, and insiders. This restriction will be in effect from Thursday, October 1, 2026, until 48 hours after the declaration and publication of the unaudited financial results for the half-year ended September 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading.

Evoq Remedies Limited has been admitted into Corporate Insolvency Resolution Process (CIRP) by the National Company Law Tribunal (NCLT), Ahmedabad. The application was filed by M/s. Harbhole Agrotech, an operational creditor, for an alleged operational debt of ₹1,95,00,000/- arising from non-refund of an advance amount for goods supply. The NCLT order dated June 9, 2026, admitted the petition filed under Section 9 of the Insolvency and Bankruptcy Code, 2016. Ms. Dipti Narayan Mundra has been proposed as the Interim Resolution Professional.

Evoq Remedies Limited is undergoing a Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. An application was filed by M/s. Harbhole Agrotech, an operational creditor, against the company on April 20, 2026, before the National Company Law Tribunal, Ahmedabad. This admission of the application signifies a critical financial distress situation for the company.

Evoq Remedies Ltd has appointed M/s. Jay Pandya & Associates as its Secretarial Auditor for the financial year 2025-26. This decision was made during the Board of Directors meeting held on May 30, 2026. The board also approved the audited financial results for the half year and year ended March 31, 2026. However, the auditor's report expresses a qualified opinion with material uncertainty related to going concern, citing non-compliance with related party loan provisions, unconfirmed debtor and supplier balances, and unpaid tax liabilities.

Evoq Remedies Ltd submitted integrated financial results for the half year and year ended March 31, 2026. The auditor's report expresses a qualified opinion with material uncertainty related to going concern. The audit highlights non-compliance with provisions governing related party loans, specifically Sections 177, 185, 188, and 189 of the Companies Act, 2013, read with Accounting Standard 18. Loans aggregating ₹670.26 lakhs were extended to related parties without prior audit committee approval, violating prescribed conditions and thresholds.

Evoq Remedies Ltd's board meeting on May 30, 2026, approved the audited financial results for the half-year and year ended March 31, 2026. Additionally, M/s. Jay Pandya & Associates were appointed as the Secretarial Auditor for the financial year 2025-26. The meeting commenced at 04:00 P.M. and concluded at 07:15 P.M.

Evoq Remedies Ltd's Board of Directors approved the audited financial results for the half year and year ended March 31, 2026, during a meeting held on May 30, 2026. The board also approved the appointment of M/s. Jay Pandya & Associates as Secretarial Auditor for the financial year 2025-26. The meeting commenced at 04:00 P.M. and concluded at 07:15 P.M.

Evoq Remedies Ltd has rescheduled its Board of Directors meeting from May 27, 2026, to May 30, 2026, at 4:00 P.M. The meeting will be held at the company's registered office in Ahmedabad to consider and approve the audited financial results for the half year and year ended March 31, 2026, along with the Auditor’s Report, and any other matter with the Chairperson's permission.

Evoq Remedies Ltd has rescheduled its Board of Directors meeting to May 27, 2026, at 4:00 P.M. The meeting, originally scheduled for May 14, 2026, will now be held at the company's registered office to consider and approve the audited financial results for the half year and year ended March 31, 2026, along with the Auditor’s Report, and any other matter with the permission of the Chairperson.